Company intelligence / Profile preview
YiChang HEC ChangJiang Pharmaceutical
Yichang, Hubei, Chinahec-changjiang.com ↗
- Ownership
- Private
- Employees
- ~1000
- Development stage
- Other
01
Overview
Strong sales leadership in anti-influenza (oseltamivir phosphate/Kewei); advancing HCV DAAs and full biosimilar insulin portfolio with up to 100% SVR12 in Phase 2 for key HCV candidate (yimitasvir phosphate); recombinant insulins reported comparable safety/effectiveness to original brand standards.
- Therapeutic areas
- CardiovascularInfectious DiseasesEndocrinology
- Modalities
- Small moleculeBiologicRecombinant proteinBiosimilar
- Industry
- Pharma
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Sunshine Lake Pharma (strategic R&D/commercial partnership, parent/shareholder)Various research collaborations
Beyond the preview
Go deeper on YiChang HEC ChangJiang Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YiChang HEC ChangJiang Pharmaceutical.